This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
Posted to
The Medical Quack .... by Barbara Duck
on 10-06-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Education, FDA, Pharmaceuticals, Pharmacogenomics, DNA Testing
It seems not a week goes by without a warning being issued from the FDA, so this looks to be a sign of the times, not to put anyone out of business, but to create an awareness. This is transparency folks and the warnings will keep on coming, so get used to it. Who knows, perhaps the competition...
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
Recently the FDA announced it was going to use the Medicare data base in the effort to mine and help find adverse drug side effects as well as other pertinent data relative to the approval and warning process in place at the FDA. This is more than likely related to the latest technology updates...
Warfarin is the second-most-likely drug, to cause adverse events requiring hospitalization. The use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding incidents. More in the way of personalized medicine and if you were a patient determined to have an adverse reaction...
The National Institute of Health sees the value of genetic profiles and is funding additional research. Duke University was the first client to use Expression Analysis and collaborates with the FDA and pharma for electronic submissions of data in an effort to accelerate drugs and diagnostics though...
A couple weeks ago I had a couple posts referencing the partner ship with Anthem Blue Cross with utilizing their data bases for such a project as well...The new FDA white paper, titled "The Sentinel Initiative -- A National Strategy for Monitoring Medical Product Safety," ... totally amazing...
Posted to
The Medical Quack .... by Barbara Duck
on 05-22-2008
Filed under: Medically Related, Technology, Insurance, My Commentaries, Genomics, healthcare, Health IT, Security, FDA, clinical trials, Medicare Part D, HL7, data bases